2 most recent filings and news items mentioning DNLI. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/DNLI/news?limit=20"
Pull DNLI filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayDenali Therapeutics entered a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds following FDA approval of AVLAYAH for Hunter syndrome. The proceeds will fund advancement of the company's clinical pipeline for lysoso
View filing at SEC.gov →The Phase 2b LUMA study of BIIB122 failed to meet primary and secondary endpoints in early-stage Parkinson's disease, prompting discontinuation in idiopathic PD while continuing a separate LRRK2 carrier study. The setback represents a significant clinical disappointment for both
View filing at SEC.gov →